Blab AI
ASHG Launches AI Initiative to Guide Responsible Use of Artificial Intelligence in Human Genetics
The American Society of Human Genetics (ASHG) announced on 8 June 2026 the launch of its Artificial Intelligence (AI) Initiative, a coordinated effort to promote the responsible and effective use of AI in human genetics and genomics.
The initiative was introduced in Rockville, Maryland, where ASHG’s headquarters are located. The society said the program will address technical and ethical issues that arise when AI tools are applied to genomic data and will produce a framework for governance, standards and education. The goal, according to the announcement, is to help researchers, clinicians and patients benefit from AI while maintaining scientific rigor and public trust.
ASHG’s AI Initiative will unfold in three main activities. First, an invitation‑only, in‑person AI Summit will bring together leaders from academia, government and industry to discuss governance and standardization of AI in genetics. Second, a two‑day virtual symposium will showcase research on AI applications in genomics. Third, a published report will summarize the summit and symposium outcomes and present a “roadmap for the future” that ASHG will use to advance AI application and governance.
The initiative is guided by a task force composed of experts in research, clinical genetics and industry. Marylyn Ritchie, PhD, Chief AI Officer at the Medical University of South Carolina, chairs the task force. Other members include Donavan Cheng, PhD (Ambry Genetics); Eric Green, MD, PhD (Illumina); Stephanie Kraft, JD (Geisinger); Danielle Luz, MD (Stanford University School of Medicine); Ankit Malhotra, PhD (Amazon Web Services); Natalie Pageler, MD (Stanford University School of Medicine); Robert Nussbaum, MD (University of California, San Francisco); Olga Troyanskya, PhD (Princeton University); Jennifer Wagner, JD, PhD (Pennsylvania State University); Nephi Walton, MD (University of Utah); and Kenny Wong, MS, CGC (xCures).
Ambry Genetics and Amazon Web Services (AWS) were announced as sponsors of the initiative. The announcement noted that the partnership would support the development of AI tools that meet the society’s standards for safety, accuracy and transparency.
ASHG is the leading global organization for human genetics, representing nearly 8,000 members that include researchers, clinicians, genetic counselors and educators. The society’s activities include the annual meeting, peer‑reviewed journals such as The American Journal of Human Genetics and Human Genetics and Genomics Advances, and advocacy for responsible genetics policies.
The launch of the AI Initiative follows a broader trend of increasing AI adoption in healthcare. AI is already used to interpret genomic sequencing, improve diagnostic accuracy, support personalized treatment plans and uncover new therapeutic targets. However, the technology also raises concerns about data privacy, algorithmic bias and the need for rigorous validation.
By establishing a governance framework and educational resources, ASHG aims to mitigate these risks. The initiative’s roadmap will provide recommendations for data stewardship, model validation, and continuous monitoring of AI systems in clinical and research settings.
The first AI Summit is scheduled for later in 2026, with details to be released by ASHG. The virtual symposium will run concurrently with the summit and will feature presentations from the task force members and other experts. The final report will be published in the spring of 2027.
The initiative signals a formal commitment by the genetics community to integrate AI responsibly. It also positions ASHG as a key stakeholder in shaping national and international standards for AI in genomics.
For more information, visit www.ashg.org or contact the society at society@ashg.org.
The initiative was introduced in Rockville, Maryland, where ASHG’s headquarters are located. The society said the program will address technical and ethical issues that arise when AI tools are applied to genomic data and will produce a framework for governance, standards and education. The goal, according to the announcement, is to help researchers, clinicians and patients benefit from AI while maintaining scientific rigor and public trust.
ASHG’s AI Initiative will unfold in three main activities. First, an invitation‑only, in‑person AI Summit will bring together leaders from academia, government and industry to discuss governance and standardization of AI in genetics. Second, a two‑day virtual symposium will showcase research on AI applications in genomics. Third, a published report will summarize the summit and symposium outcomes and present a “roadmap for the future” that ASHG will use to advance AI application and governance.
The initiative is guided by a task force composed of experts in research, clinical genetics and industry. Marylyn Ritchie, PhD, Chief AI Officer at the Medical University of South Carolina, chairs the task force. Other members include Donavan Cheng, PhD (Ambry Genetics); Eric Green, MD, PhD (Illumina); Stephanie Kraft, JD (Geisinger); Danielle Luz, MD (Stanford University School of Medicine); Ankit Malhotra, PhD (Amazon Web Services); Natalie Pageler, MD (Stanford University School of Medicine); Robert Nussbaum, MD (University of California, San Francisco); Olga Troyanskya, PhD (Princeton University); Jennifer Wagner, JD, PhD (Pennsylvania State University); Nephi Walton, MD (University of Utah); and Kenny Wong, MS, CGC (xCures).
Ambry Genetics and Amazon Web Services (AWS) were announced as sponsors of the initiative. The announcement noted that the partnership would support the development of AI tools that meet the society’s standards for safety, accuracy and transparency.
ASHG is the leading global organization for human genetics, representing nearly 8,000 members that include researchers, clinicians, genetic counselors and educators. The society’s activities include the annual meeting, peer‑reviewed journals such as The American Journal of Human Genetics and Human Genetics and Genomics Advances, and advocacy for responsible genetics policies.
The launch of the AI Initiative follows a broader trend of increasing AI adoption in healthcare. AI is already used to interpret genomic sequencing, improve diagnostic accuracy, support personalized treatment plans and uncover new therapeutic targets. However, the technology also raises concerns about data privacy, algorithmic bias and the need for rigorous validation.
By establishing a governance framework and educational resources, ASHG aims to mitigate these risks. The initiative’s roadmap will provide recommendations for data stewardship, model validation, and continuous monitoring of AI systems in clinical and research settings.
The first AI Summit is scheduled for later in 2026, with details to be released by ASHG. The virtual symposium will run concurrently with the summit and will feature presentations from the task force members and other experts. The final report will be published in the spring of 2027.
The initiative signals a formal commitment by the genetics community to integrate AI responsibly. It also positions ASHG as a key stakeholder in shaping national and international standards for AI in genomics.
For more information, visit www.ashg.org or contact the society at society@ashg.org.
